We recently published 10 Stocks with Eye-Popping Gains; 5 Jump to New Highs. Gilead Sciences, Inc. (NASDAQ:GILD) is one of ...

Gilead Sciences Inc. (NASDAQ:GILD) is one of the most undervalued quality stocks to buy according to hedge funds. On July 25, the European Medicines Agency’s Committee for Medicinal Products for Human ...

Gilead Sciences, Inc. (NASDAQ:GILD) will release earnings results for the second quarter, after the closing bell on Thursday, ...

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.7% in the morning session after the company ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q2 CY2025 results , with sales up 1.8% year on year to $7.08 ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting results this Thursday after market close. Here’s ...

In the latest trading session, Gilead Sciences (GILD) closed at $105.93, marking a -1.18% move from the previous day. Meanwhile, the Dow lost 0.25%, and the Nasdaq, a tech-heavy index, added 0.31% ...

In the latest trading session, Gilead Sciences (GILD) closed at $109.06, marking a -2.7% move from the previous day. This change lagged the S&P 500's daily loss of 0.4%. Meanwhile, the Dow lost 0. ...

Explore the exciting world of Gilead Sciences (NASDAQ: GILD) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends ...

Gilead reported revenues of $6.67 billion in the last reported quarter, representing a year-over-year change of -0.3%. EPS of $1.81 for the same period compares with -$1.32 a year ago.

Gilead Sciences is currently sporting a Zacks Rank of #2 (Buy). The Zacks Consensus Estimate for GILD's full-year earnings has moved 0.7% higher within the past quarter.